Website value calculator & SEO Checker => ultragenyx.com

Q: What IP ultragenyx.com has?

The domain ultragenyx.com has IP 138.91.252.236 . An IP address is a string of numbers used to make devices accessible for communication.

SEO report with information and free domain appraisal for ultragenyx.com. It is a domain hosted in . Its server is hosted on IP 138.91.252.236. The domain is ranked at the number 425892 as a world ranking of web pages. According to estimated data we have access to potential gains of this site are 144 dollars per month. In annual terms, the domain ultragenyx.com could be earning more than 1729 dollars. If someone wanted to buy the domain a good selling price would be 17288 dollars.

These data are estimated and can not be taken as 100 % real. Only give an estimate of profits depending on the subject and the traffic generated by ultragenyx.com . The estimated number of unique visitors accessing ultragenyx.com is 1259. Thus the total number of people who visit this page per month would be 37763 people.

Domain Authority

SEO Score

☰ Report Resume

SEO score
Speed
Page Load Time
Current Ip of the domain: 138.91.252.236
Charset of page: UTF-8
Total Keywords: 518
Total Links:

Anchor text
Type
Link
English
follow
/
Português
follow
/brazilian-portuguese
English
follow
/canadian-english
Français
follow
/canadian-french
Patient Resources
follow
/our-purpose/supporting-access-for-patients#patient-resources
Investors & Media
follow
https://ir.ultragenyx.com/
Careers
follow
https://www.ultragenyx.com/careers/
Contact
follow
https://www.ultragenyx.com/our-company/contact/

follow
/
Our Purpose
follow
https://www.ultragenyx.com/our-purpose/
Supporting Access for Patients
follow
https://www.ultragenyx.com/our-purpose/supporting-access-for-patients/
Approved Medicines
follow
/our-purpose/supporting-access-for-patients/
Investigational Therapies
follow
/our-purpose/supporting-access-for-patients#investigational-therapies
Patient/Advocacy Resources
follow
/our-purpose/supporting-access-for-patients#patient-resources
Our Responsibility
follow
https://www.ultragenyx.com/our-purpose/our-responsibility/
Grants and Charitable Contributions
follow
https://www.ultragenyx.com/our-purpose/our-responsibility/grants-and-charitable-contributions/
Our Company
follow
https://www.ultragenyx.com/our-company/
Our Leaders
follow
https://www.ultragenyx.com/our-company/our-leaders/
Our Partners
follow
https://www.ultragenyx.com/our-company/our-partners/
Contact Us
follow
https://www.ultragenyx.com/our-company/contact/
Our Medicines
follow
https://www.ultragenyx.com/our-medicines/
Crysvita® (burosumab-twza)
follow
https://www.ultragenyx.com/our-medicines/crysvita/
Dojolvi® (triheptanoin)
follow
https://www.ultragenyx.com/our-medicines/dojolvi/
Mepsevii® (vestronidase alfa—vjbk)
follow
https://www.ultragenyx.com/our-medicines/mepsevii/
Our Research
follow
https://www.ultragenyx.com/our-research/
Our Science
follow
https://www.ultragenyx.com/our-research/our-science/
Our Pipeline
follow
https://www.ultragenyx.com/our-research/our-pipeline/
DTX401 for GSDIa
follow
https://www.ultragenyx.com/our-research/our-pipeline/dtx401-for-gsdia/
DTX301 for OTC
follow
https://www.ultragenyx.com/our-research/our-pipeline/dtx301-for-otc/
UX701 for Wilson Disease
follow
https://www.ultragenyx.com/our-research/our-pipeline/ux701-for-wilson-disease/
UX143 for Osteogenesis Imperfecta
follow
https://www.ultragenyx.com/our-research/our-pipeline/ux143-for-osteogenesis-imperfecta-mereo-biopharma-collaboration/
GTX-102 for Angelman Syndrome
follow
https://www.ultragenyx.com/our-research/our-pipeline/gtx-102-for-angelman-syndrome-genetx-collaboration/
UX053 for GSDIII
follow
https://www.ultragenyx.com/our-research/our-pipeline/ux053-for-gsdiii/
Our Clinical Trial Transparency Commitment
follow
https://www.ultragenyx.com/our-research/our-pipeline/our-clinical-trial-transparency-commitment/
Our Gene Therapy Platform
follow
https://www.ultragenyx.com/our-research/our-gene-therapy-platform/
Patient Resources
follow
/our-purpose/supporting-access-for-patients#patient-resources
Investors & Media
follow
https://ir.ultragenyx.com/
Careers
follow
https://www.ultragenyx.com/careers/
Contact
follow
https://www.ultragenyx.com/our-company/contact/
Learn More
follow
/our-company/
(888) 384-0599
follow
mailto:8883840599
Patients We are committed to improving the lives of people with rare and ultra-rare genetic diseases through new medicines, educational initiatives, patient advocacy, research, and access to information.Learn more
follow
https://www.ultragenyx.com/our-purpose/supporting-access-for-patients/
Pipeline Our diverse portfolio of approved medicines and investigational therapies is advancing first- or best-in-class treatments for diseases that exhibit a clear biology for treatment and are severely underserved by current standard of care.Learn more
follow
https://www.ultragenyx.com/our-research/our-pipeline/
Culture We maintain an environment that puts people first. This includes patients, their families and caregivers, and our employees. We respect the responsibility that comes with developing medicines for rare diseases.Learn more
follow
https://www.ultragenyx.com/careers#culture
Ultragenyx Reports Third Quarter 2021 Financial Results and Corporate UpdateNovember 2, 2021
follow
http://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-reports-third-quarter-2021-financial-results-and
Ultragenyx to Host Conference Call for Third Quarter 2021 Financial Results and Corporate UpdateOctober 26, 2021
follow
http://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-host-conference-call-third-quarter-2021-financial
Ultragenyx to Present at Jefferies Gene Therapy/Editing SummitOctober 25, 2021
follow
http://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-present-jefferies-gene-therapyediting-summit-1
Read More News
follow
https://ir.ultragenyx.com/press-releases
Learn More
follow
/covid-19-information
Our Purpose
follow
https://www.ultragenyx.com/our-purpose/
Supporting Access for Patients
follow
https://www.ultragenyx.com/our-purpose/supporting-access-for-patients/
Our Responsibility
follow
https://www.ultragenyx.com/our-purpose/our-responsibility/
Our Company
follow
https://www.ultragenyx.com/our-company/
Our Leaders
follow
https://www.ultragenyx.com/our-company/our-leaders/
Our Partners
follow
https://www.ultragenyx.com/our-company/our-partners/
Contact Us
follow
https://www.ultragenyx.com/our-company/contact/
Our Medicines
follow
https://www.ultragenyx.com/our-medicines/
Crysvita® (burosumab-twza)
follow
https://www.ultragenyx.com/our-medicines/crysvita/
Dojolvi® (triheptanoin)
follow
https://www.ultragenyx.com/our-medicines/dojolvi/
Mepsevii®(vestronidase alfa—vjbk)
follow
https://www.ultragenyx.com/our-medicines/mepsevii/
Our Research
follow
https://www.ultragenyx.com/our-research/
Our Science
follow
https://www.ultragenyx.com/our-research/our-science/
Our Pipeline
follow
https://www.ultragenyx.com/our-research/our-pipeline/
Our Gene Therapy Platform
follow
https://www.ultragenyx.com/our-research/our-gene-therapy-platform/
Careers
follow
https://www.ultragenyx.com/careers/
Culture
follow
/careers#culture
Benefits
follow
https://www.ultragenyx.com/careers/benefits/
Talent Network
follow
https://www.ultra-talent.com/
Emerging Talent
follow
https://www.ultragenyx.com/careers/emerging-talent/
Jobs
follow
https://www.ultragenyx.com/careers/jobs/
Investors & Media
follow
https://ir.ultragenyx.com/
Press Releases
follow
https://ir.ultragenyx.com/press-releases
Events & Presentations
follow
https://ir.ultragenyx.com/events-presentations
Governance
follow
https://ir.ultragenyx.com/corporate-governance
SEC Filings
follow
https://ir.ultragenyx.com/financial-information/sec-filings
Stock Information
follow
https://ir.ultragenyx.com/stock-information
Analyst Coverage
follow
https://ir.ultragenyx.com/stock-information/analyst-coverage
Investor FAQ
follow
https://ir.ultragenyx.com/investor-faqs
www.UltraRareAdvocacy.com
follow
http://www.UltraRareAdvocacy.com
www.UltraCareSupport.com
follow
http://www.UltraCareSupport.com

follow
/

follow
https://www.linkedin.com/company/ultragenyx-pharmaceutical-inc-/

follow
https://www.facebook.com/Ultragenyx/?rf=1531080217184360
Privacy Policy
follow
https://www.ultragenyx.com/privacy-policy/
Cookie Policy
follow
https://www.ultragenyx.com/cookie-policy/
Cookie Policy
follow
/cookie-policy
Privacy Policy
follow
/privacy-policy
Social signals
Title: 60 characters.
Description: 121 characters.
Domain Authority
Monthly pages viewed: 37763
Estimated worth: 17288 dollars

☷ Major sections

❀ Whois

We have developed a useful service for retrieve WhoIs information. "Whois" is a term that begins from the early days of the Internet, based on Unix operating system and university networks. On the Unix console, the command "whois" tries to determine the identity of the domain's registrant.

It is a means for Internet users to query various types of information such as IP addresses, user data and also domain data.

✦ SEO Report

Title / Meta tags

Ultragenyx Treatment of Rare and Ultra-rare Genetic Diseases

Ultragenyx is leading the future of rare disease medicine. We are committed in moving the rare disease community forward.

Image Analysis

A right example for an HTML image tag:

For SEO performance, you must write an alternative text. The alternative text must describe the image's content. Also, the alt tag is used for blind people. Their browsers tell them all about the description of the image.

Heading

Content Analysis

Code Analysis

We have not found hyphens (-) or underscores (_) in your URL. Google and expert domainers do not recommend buying domains with hyphens or underscores.

☛ Speed Analysis

When a visitor came to your website you can not fail. The user wants your page to load in a second. You know that it is difficult sometimes to display content in the first second but if the user has to wait too much time you can lose that user. If your page is too slow, you will lose a lot of web traffic. Your project URL load time is ms, it is class speed. This speed not fine and need to be improved. It is over the average. Our Speed analyzer has shown that www.ultragenyx.com is as follows:

A huge portion of visitors to your website are usually in rush and nobody is fond of waiting too much before your website loads its content. If your website is slow, you will lose a lot of visitors. Your homepage load time is ms is class speed. This speed not fine and need to be improved. It is over the average. Our Speed analyzer has shown that www.ultragenyx.com is as follows:

Speed:

Page Load Time: ms

⚐ Page Analysis

⚏ CSS Class names

yoast-schema-graph, home page-template page-template-templates page-template-template-builder page-template-templatestemplate-builder-php page page-id-412 page-home, header-utility, container, utility-container, select-country, selected-country, country country-usa active-country, icon-usa, fas fa-chevron-down, country-options, country country-brazil, icon-brazil, country country-canada, icon-canada, canada-english, canada-french, menu-header-utility-container, menu, patient-resources-link menu-item menu-item-type-custom menu-item-object-custom menu-item-158, investors-and-media-link menu-item menu-item-type-custom menu-item-object-custom menu-item-648, careers-link menu-item menu-item-type-post_type menu-item-object-page menu-item-157, contact-link menu-item menu-item-type-post_type menu-item-object-page menu-item-155, container custom-mobile-container, header-navigation, logo-ultragenyx, menu-header-main-container, menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-140, sub-menu, menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-237, menu-item menu-item-type-custom menu-item-object-custom menu-item-460, menu-item menu-item-type-custom menu-item-object-custom menu-item-461, menu-item menu-item-type-custom menu-item-object-custom menu-item-462, menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-236, menu-item menu-item-type-post_type menu-item-object-page menu-item-356, menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-138, menu-item menu-item-type-post_type menu-item-object-page menu-item-230, menu-item menu-item-type-post_type menu-item-object-page menu-item-229, menu-item menu-item-type-post_type menu-item-object-page menu-item-468, menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-139, mobile-block menu-item menu-item-type-post_type menu-item-object-page menu-item-232, mobile-block menu-item menu-item-type-post_type menu-item-object-page menu-item-233, mobile-block menu-item menu-item-type-post_type menu-item-object-page menu-item-234, menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-888, menu-item menu-item-type-post_type menu-item-object-page menu-item-141, menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-244, menu-item menu-item-type-post_type menu-item-object-page menu-item-241, menu-item menu-item-type-post_type menu-item-object-page menu-item-240, menu-item menu-item-type-post_type menu-item-object-page menu-item-247, menu-item menu-item-type-post_type menu-item-object-page menu-item-344, menu-item menu-item-type-post_type menu-item-object-page menu-item-345, menu-item menu-item-type-post_type menu-item-object-page menu-item-346, menu-item menu-item-type-post_type menu-item-object-page menu-item-347, menu-item menu-item-type-post_type menu-item-object-page menu-item-239, utility-navigation-mobile, menu-icon menu-icon-3, bar bar-1, bar bar-2, bar bar-3, menu-txt, main, hero-main-block, hero-main-container, hero-main, row, col-sm-7 col-md-6, mt-4, btn-main, sr-only, intro, row justify-content-center, col-sm-12 col-md-10 col-lg-8, like-h3, fbk, overlapping-col-block, col-xs-12 col-sm-4, cta-card, cta-card-photo, cta-card-info, cta-card-link, cta-card-content, pink, far fa-chevron-right, latest-announcements-block pt-5 pb-5, purple, row align-bottom, col-sm-12 col-md-4 announcement-col, announcement-link, announcement, announcement-inner, announcement-title, announcement-date, announcement-more, text-block , container-slim, text-center text-md-left, modal fade, modal-dialog, modal-content, modal-body, modal-title, modal-action, modal-footer, footer, footer-navigation, menu-footer-main-container, menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-104, menu-item menu-item-type-post_type menu-item-object-page menu-item-107, menu-item menu-item-type-post_type menu-item-object-page menu-item-106, menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-96, menu-item menu-item-type-post_type menu-item-object-page menu-item-98, menu-item menu-item-type-post_type menu-item-object-page menu-item-97, menu-item menu-item-type-post_type menu-item-object-page menu-item-624, menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-100, menu-item menu-item-type-post_type menu-item-object-page menu-item-101, menu-item menu-item-type-post_type menu-item-object-page menu-item-102, menu-item menu-item-type-post_type menu-item-object-page menu-item-103, menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-889, menu-item menu-item-type-post_type menu-item-object-page menu-item-108, menu-item menu-item-type-post_type menu-item-object-page menu-item-115, menu-item menu-item-type-post_type menu-item-object-page menu-item-110, menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-82, menu-item menu-item-type-custom menu-item-object-custom menu-item-852, menu-item menu-item-type-post_type menu-item-object-page menu-item-83, menu-item menu-item-type-custom menu-item-object-custom menu-item-1207, menu-item menu-item-type-post_type menu-item-object-page menu-item-428, menu-item menu-item-type-post_type menu-item-object-page menu-item-85, menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-649, menu-item menu-item-type-custom menu-item-object-custom menu-item-650, menu-item menu-item-type-custom menu-item-object-custom menu-item-651, menu-item menu-item-type-custom menu-item-object-custom menu-item-652, menu-item menu-item-type-custom menu-item-object-custom menu-item-653, menu-item menu-item-type-custom menu-item-object-custom menu-item-654, menu-item menu-item-type-custom menu-item-object-custom menu-item-655, menu-item menu-item-type-custom menu-item-object-custom menu-item-656, other-navigation, other-nav-headline, menu-footer-other-container, menu-item menu-item-type-custom menu-item-object-custom menu-item-119, menu-item menu-item-type-custom menu-item-object-custom menu-item-120, logo-copyright, col-sm-6 logo-block, col-sm-6 copyright-block, menu-footer-social-container, linkedin-link external-li menu-item menu-item-type-custom menu-item-object-custom menu-item-154, fab fa-linkedin-in, facebook-link external-li menu-item menu-item-type-custom menu-item-object-custom menu-item-153, fab fa-facebook-f, menu-footer-utility-container, menu-item menu-item-type-post_type menu-item-object-page menu-item-150, menu-item menu-item-type-post_type menu-item-object-page menu-item-630, cookie-banner, col-md-9, copy-wrap, col-md-3 col-buttons, btn-wrap, btn-secondary,

Ω HTTP Header Analysis

✪ Source Analysis

Your website is made from CSS files, images and javascript sources. We count all the files and their size. This is vital data about the performance of your website.